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Abstract
Background: The tetraspan protein CD63, originally described as a stage-specific melanoma
antigen but also present in a number of normal cells, regulates melanoma cell growth in nude mice,
motility in serum containing media, and adhesion to several extracellular matrix proteins. CD63
has been reported to associate with β1 and β2 integrins, but the mechanism of signal transduction
by CD63 is not clear. This study examined whether CD63 is associated with protein kinase and
can transmit signals in melanoma cells.
Methods: Immunoprecipitation and radiolabeling were used to test for association of protein
kinase activity with CD63. Adhesion of cells to monoclonal antibodies immobilized to microtiter
plates was used to examine the ability of CD63 to transmit signals.
Results: CD63 was capable of transmitting a signal in melanoma cells that required extracellular
calcium. In the absence of extracellular calcium at the time of binding to the CD63 mAb, the cell
was no longer responsive to stimulation by CD63. Immunoprecipitation studies demonstrated
protein kinase activity associated with CD63, and phosphoamino acid analysis revealed that most
of this protein kinase activity was due to serine kinase activity.
Conclusion: The current study suggests that serine protein kinase activity associated with CD63
may play a role in signaling by CD63 in melanoma cells.
Background
CD63 was initially described as the ME491 antigen of
melanoma cells [1-8]. CD63 is not expressed in normal
melanocytes, but is expressed in nevi and many
melanoma cells. CD63 is also expressed in a number of
normal cells [1-5,9-18]. A number of studies have sug-
gested that CD63 may regulate melanoma cell functions.
Transfection with CD63 of NIH-3T3 cells transformed
with H-ras, resulted in cells with lower growth rates fol-
lowing subcutaneous injection in nude mice [19]. Trans-
fection of the CD63 negative melanoma cell line KM3
with genomic CD63 resulted in cells with similar in vitro
growth rates as control cells, but much slower growth rates
in vivo when cells were injected intradermally in nude
mice [20]. In addition, intravenous injection of CD63
transfected KM3 cells resulted in fewer peritoneal and sub-
cutaneous metastases [20]. These data, therefore, suggest
that CD63 may regulate in vivo growth and metastatic
capability [20]. Finally, transfection of the highly motile
KM3 cells with CD63 resulted in suppression of in vitro
motility in serum-containing media that was potentiated
by CD63 mAbs, and increased adhesion and migration on
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fibronectin, laminin, and collagen [21]. In contrast, trans-
fection of antisense CD63 cDNA into melanoma cells
endogenously expressing CD63, resulted in increased cell
motility and invasiveness in vitro[22]. Thus, CD63
appears capable of regulating melanoma cell functions,
although the mechanism of this regulation is unclear.
CD63 is a member of the tetraspan family, traversing the
membrane four times and having a major extracellular
loop and a small extracellular loop, with short intracellu-
lar amino and carboxy termini [1,2,4,5,14,18,23-25]. The
intracellular domains of CD63 are small and have no clear
motif known to be involved in signal transmission.
In this study, the properties of the adhesion of melanoma
cells to immobilized CD63 mAb suggested that CD63 was
capable of transmitting a signal that requires extracellular
calcium. Protein kinase activity, predominantly in the
form of serine kinase activity, was found to be associated
with CD63 in these cells. The association of serine protein
kinase activity with CD63 may play a role in signaling by
CD63 in melanoma.
Methods
Cell Culture
Highly metastatic human melanoma cells, A375SM,
which were selected by in vivo experimental metastasis
assays of parent A375P cells in nude mice [26] were kindly
provided by Dr. I. J. Fidler (M.D. Anderson Hospital Can-
cer Center, Houston, TX). The cells were maintained in
Eagle's Minimum Essential Medium (EMEM) supple-
mented with 10% FBS, vitamin solution, 50 mg/ml gen-
tamycin, and 1 mM sodium pyruvate. Cells were routinely
used after fewer than 15 passages from frozen stocks in
order to minimize phenotypic drift.
Monoclonal antibodies (mAbs)
The CD63 mAbs, AHN-16 (IgG2a), AHN-16.1 (IgG1),
AHN-16.2 (IgG2b), AHN-16.3 (IgG2b), and AHN-16.5
(IgG1) were previously described [15]. mAb U131 (IgG1)
was previously described [27]. mAb 9.2.27 that recognizes
the core protein of melanoma associated antigen (MCSP)
[28] was a gift of Dr. Ralf Reisfeld (Scripps Clinic, La Jolla,
CA). Fab fragments of AHN-16 were prepared by using
immobilized papain according to the manufacturer's
instruction (Pierce, Rockford, IL), and their purity was
confirmed by SDS-PAGE analysis.
Cell adhesion assays
Cell adhesion assays to immobilized mAbs were per-
formed as described previously [29]. Briefly, 96-well
plates were coated with 50 ul of goat anti-mouse IgG Fc
(Organon Teknika Corp., Durham, NC) overnight at
37°C and then blocked with PBS containing 2 mg/ml BSA
for 3 h at 37°C. The purified mAbs were diluted in PBS,
dispersed into each well at 1 ug/ml in 50 ul, incubated for
3 to 4 h at 37°C, and then washed 2 times with PBS. Sub-
confluent A375SM cells that had been radiolabeled over-
night with 3H-thymidine (3H-TdR, specific activity 6.7 Ci/
mmol; NEN Research Products, Boston, MA), were har-
vested by rinsing with PBS containing 1 mM EDTA,
washed two times with EMEM/BSA (EMEM containing 2
mg/ml BSA and 15 mM Hepes, pH 7.2), and adjusted to a
concentration of 105 cells/ml in the same medium. When
cell adhesion assays were carried out in the presence of 10
mM EDTA or EGTA, cells were resuspended in EMEM/BSA
containing 10 mM EDTA or EGTA. An aliquot of 100 ul of
the cell suspension was dispersed into each well and incu-
bated for 60 min at 37°C. For inhibiting cell adhesion to
the immobilized AHN-16, cells were preincubated with
Fab fragments of AHN-16 or of normal mouse IgG for 20
min at room temperature. Cell adhesion assays were car-
ried out in the continuous presence of these Fab fragments
for 60 min at 37°C. The assays were terminated by aspi-
rating loosely bound and unbound cells from the wells.
Bound radioactivity was determined in a liquid scintilla-
tion counter (Beckman Model 3801 Liquid Scintillation
Counter).
Flow cytometry
Cells were harvested as described above, and washed 3
times with RPMI 1640 containing 1% heat-inactivated
goat serum, 20 mM HEPES, and 0.02% NaN3(FACS
buffer). Cells were resuspended in the FACS buffer at a
concentration of 105 cells/ml with 10 ug/ml normal goat
IgG for 30 min at 4°C and then washed 3 times with the
FACS buffer. An aliquot of 1 ml of cell suspension was
incubated with 5 ug/ml of mAbs for 30 min at 4°C with
mixing every 5 min. Cells were washed 3 times with the
FACS buffer and then incubated with FITC conjugated
goat anti-mouse IgG (final dilution of 1: 500) at 4°C for
40 min with mixing every 5 min. The binding of the pri-
mary and the secondary mAbs were maximal under these
experimental conditions. Cells were washed 3 times with
the FACS buffer and resuspended in 200 ul of PBS con-
taining 2% formaldehyde. Cells were analyzed on a FACS
Star (Becton-Dickinson, Mt. View, CA).
Protein kinase assay
Immunoprecipitation was performed as previously
described with minor modifications [30]. Briefly, 2 × 107
cells were suspended in 1.1 ml of Brij solubilization buffer
[20 mM Tris-HCl, pH 8.2, 150 mM NaCl, 1 mM PMSF, 2
mM MgCl2, 0.02% NaN3, and 1.0% Brij 58 (Pierce)], and
incubated on ice for 15 min. The suspensions were then
centrifuged at 9,800 × g for 15 min at 4°C. The resulting
supernatants were used for immunoprecipitation or ana-
lyzed by SDS-PAGE directly.Journal of Translational Medicine 2005, 3:42 http://www.translational-medicine.com/content/3/1/42
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For immunoprecipitations, 1 ml of 10% Staphylococcu-
saureus (Pansorbin A, Calbiochem, La Jolla, CA) was
mixed with 100 µl of rabbit anti-mouse IgGH+L (Organon
Teknika, Westchester, PA), and the mixture was incubated
at 4°C for 1 hr. One ml of buffer A (1 mg/ml BSA, 0.05%
NP-40, 20 mM Tris-HCl, pH 7.6, 100 mM NaCl, 1 mM
EDTA, 0.05% NaN3) was added and the Pansorbin A-anti-
body complex was recovered by centrifuging at 2000 × g
for 10 min at 4°C and resuspended in 390 µl of buffer A
and 40 µl of ascites containing the indicated monoclonal
antibody, or normal mouse serum (NMS) was added, and
the mixtures were incubated for 2 hr at 4°C. The Pan-
sorbin A-antibody complex was recovered by centrifuging
at 2000 × g for 10 min at 4°C, washed once with 1 ml of
buffer A, and resuspended in 1 ml of Brij-SA buffer (1 mg/
ml BSA, 0.05% Brij 58, 20 mM Tris-HCl, pH 7.6, 100 mM
NaCl, 1 mM EDTA, 0.05% NaN3). Cell proteins were then
immunoprecipitated in reaction mixtures containing the
cell extract, Pansorbin A-bound antibody complex, 20
mM Tris-HCl, pH 8.2, 100 mM NaCl, 0.5% Brij 58, 1 mM
EDTA, 0.125 mg/ml gelatin, and 1 mM PMSF in a total
volume of approximately 350 µl in 10 × 75 mm glass
tubes. After 1 hr at 4°C, the mixture was washed three
times with Brij wash buffer (20 mM Tris-HCl, pH 8.2, 150
mM NaCl, 1 mg/ml BSA, 0.5% Brij 58, 2 mM MgCl2,
0.125 mg/ml gelatin, 1 mM PMSF, and 0.02% NaN3) and
then once with NaCl-HEPES (145 mM NaCl, 20 mM
HEPES, pH 7.3). Immunoprecipitates were suspended in
30 µl of NaCl-HEPES. Thirty ul of labeling buffer (0.1%
Brij 58, 6 mM MnCl2, 40 mM MgCl2, 200 uM Na3VO4,
200 uM Na2MoO4, and 10 µCi of [γ-32P]ATP) was then
added, and the mixtures were incubated for 10 min at
23°C. The reaction was stopped by adding 4 × Laemmli
sample buffer, incubated at 100°C for 2 min, and ana-
lyzed by SDS-PAGE [31]. Molecular weight standards
were purchased from Sigma. Gel slabs were stained, dried,
and subjected to autoradiography by using Dupont
Cronex film.
Phosphoamino acid analysis
Phosphoamino acid analyses were performed as previ-
ously described [32,33]. Briefly, radiolabeled proteins
resolved by SDS-PAGE were transblotted onto Immo-
bilon-P (PVDF) paper (Millipore Corp, Bedford, MA),
localized by autoradiography, and excised. The proteins
on the PVDF were then hydrolyzed in vacuo in constantly
boiling 6 M HCl for 2 hr at 110°C. The HCl was removed
by evaporation using a SpeedVac (Savant Instruments).
The dried, partially hydrolyzed samples were then dis-
solved in water containing phosphoserine (P-S), phos-
phothreonine (P-T), and phosphotyrosine (P-Y) (Sigma)
each at 1 mg/ml. The samples were then spotted on alu-
minum sheets precoated with silica gel (0.2 mm layer
thickness, 11 cm height, Merck Laboratories, EM Science,
Gibbstown, NJ) and resolved by one-dimensional thin
layer chromatography in ethanol: 25% NH4OH (3.5:1.6).
The chromatography cycle was repeated three times to
achieve optimal separation. Between cycles, plates were
air dried followed by chromatography in the same sol-
vent. The radiolabeled phosphoamino acids were
detected by autoradiography using X-Omat AR film.
Concentration dependence of A375SM melanoma cell adhe- sion to immobilized CD63 mAb Figure 1
Concentration dependence of A375SM melanoma cell adhe-
sion to immobilized CD63 mAb. Plates were coated with 
various concentrations of the CD63 mAb (AHN-16) (open 
circles), the anti-MCSP mAb 9.2.27 (open squares), or nor-
mal mouse IgG (open triangles) as described in Materials and 
Methods. Cell adhesion assays were performed for 30 min. 
Results are shown as percent adhesion +/- SEM. A duplicate 
experiment gave similar results.
Table 1: Human melanoma cell adhesion to immobilized CD63 
mAbs
mAba Specificity Cell adhesion (%)b
AHN-16 CD63 59
AHN-16.1 CD63 29
AHN-16.2 CD63 55
AHN-16.3 CD63 63
AHN-16.5 CD63 29
U131 not clustered 3
IgGc N/A 4
9.2.27 MCSP 88
a. Each mAb was coated on plates at a concentration of 1 ug/ml.
b. Assays of adhesion of A375SM melanoma cells to mAbs 
immobilized on plastic were performed for 30 min. as described in the 
text. Cell adhesion is expressed as the percent of the total number of 
cells added. Values are the means of four replicates that agreed within 
10 %. A duplicate experiment gave similar results. c. Normal mouse 
IgGJournal of Translational Medicine 2005, 3:42 http://www.translational-medicine.com/content/3/1/42
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Results
Human melanoma cells adhere to immobilized CD63 mAbs
To establish a simple assay of CD63 signaling in
melanoma cells, we tested several CD63 mAbs including
AHN-16, AHN-16.1, AHN-16.2, AHN-16.3, and AHN-
16.5 for their ability to promote A375SM human
melanoma cell adhesion as previously described [29].
CD63 expression on these cells was confirmed using flow
cytometry with five CD63 mAbs as described in the Meth-
ods (data not shown). Each of the mAbs was immobilized
on plastic microtiter plates as described in the Materials
and Methods. Cell adhesion assays were carried out for 30
min. At coating concentrations of 1 ug/ml, each of the
CD63 mAbs promoted melanoma cell adhesion (Table
1). In contrast, the control antibodies normal mouse IgG
(IgG) and the unclustered mAb U131 did not. As
expected, the anti-MCSP mAb 9.2.27 promoted high lev-
els of cell adhesion, consistent with our previous results
[29]. AHN-16 promoted cell adhesion in a concentration-
dependent manner (Fig 1). As expected [29], an anti-
melanoma associated proteoglycan mAb (9.2.27) also
promoted cell adhesion in a concentration-dependent
manner (Fig 1). Normal mouse IgG failed to promote
melanoma cell adhesion (Fig 1).
In order to confirm that the cell adhesion to immobilized
AHN-16 was due to reactivity with the CD63 epitope, Fab
fragments of AHN-16 and normal mouse IgG were pre-
pared as described in the Materials and Methods, and
tested for their ability to inhibit melanoma cell adhesion
to immobilized AHN-16. Fab fragments of AHN-16, but
not of normal mouse IgG, effectively inhibited cell adhe-
sion to AHN-16 in a concentration dependent manner
(Fig 2). At the highest concentration of AHN-16 Fab frag-
ment (20 ug/ml), cell adhesion was inhibited by 90%.
These results confirmed that cell adhesion to immobilized
AHN-16 was dependent on the antigen binding site.
Human melanoma cell adhesion to immobilized CD63 
mAb is inhibited by chelerythrine
In order to study the signaling pathways by which CD63
may transmit signals, cell adhesion assays were carried out
in the presence of chelerythrine, a potent and specific
inhibitor of protein kinase C [34]. Melanoma cells were
preincubated with various concentrations of chelerythrine
or genistein, a selective tyrosine protein kinase inhibitor,
for 20 min at 37°C prior to cell adhesion assays. Cheler-
ythrine inhibited melanoma cell adhesion to immobi-
lized AHN-16 in a concentration dependent manner with
an IC50 of approximately 2.5 uM (Fig 3). Chelerythrine
did not alter surface expression of CD63 as determined by
flow cytometry (not shown). In contrast, genistein did not
affect cell adhesion to immobilized AHN-16 under these
conditions at concentrations up to 50 ug/ml (not shown).
However, cell adhesion to mAb 9.2.27 was totally resist-
Chelerythrine inhibited cell adhesion to immobilized CD63  mAb Figure 3
Chelerythrine inhibited cell adhesion to immobilized CD63 
mAb. Plates were coated with 0.1 ug/ml of the CD63 mAb 
AHN-16 or the anti-MCSP mAb 9.2.27 as described in Mate-
rials and Methods. Cells were preincubated with various con-
centrations of chelerythrine for 20 min before adding the 
cells to the plates for the cell adhesion assays. Cell adhesion 
assays were performed for 30 min. Results are shown as per-
cent adhesion +/- SEM. A duplicate experiment gave similar 
results.
Melanoma cell adhesion to immobilized CD63 mAb was  inhibited by Fab fragments Figure 2
Melanoma cell adhesion to immobilized CD63 mAb was 
inhibited by Fab fragments. Plates were coated with 0.1 ug/ml 
of the CD63 mAb AHN-16 as described in Materials and 
Methods. Cells were preincubated with various concentra-
tions of Fab fragments of AHN-16 (open circles) or of nor-
mal mouse IgG (closed circles) for 20 min before adding the 
cells to the plates for the cell adhesion assays. Cell adhesion 
assays were performed for 30 min. Results are shown as per-
cent adhesion +/- SEM. A duplicate experiment gave similar 
results.Journal of Translational Medicine 2005, 3:42 http://www.translational-medicine.com/content/3/1/42
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ant to both chemicals (not shown). These results sug-
gested that protein kinase C plays a role in cell adhesion
to immobilized CD63 mAb.
Human melanoma cell adhesion to immobilized CD63 
mAb requires external Ca2+
We next examined the effects of extracellular Ca2+ on
melanoma cell adhesion to immobilized CD63 mAbs.
Human melanoma cell adhesion to three different immo-
bilized CD63 mAbs was almost totally inhibited by EGTA,
indicating that external Ca2+ plays an important role in
human melanoma cell adhesion to the mAbs (Fig 4, top).
Cells did not adhere to immobilized CD63 mAbs in the
absence of calcium, suggesting that this adhesion is an
active process. In contrast, cell adhesion to immobilized
mAb 9.2.27 was totally resistant to EGTA (Fig 4A, top).
EGTA itself was not inhibitory since cell adhesion to
AHN-16 was similar to control cell adhesion levels when
a normal Ca2+ level was generated by adding 10 mM Ca2+
to the cells in EGTA (Fig 4B, bottom). EGTA did not inter-
fere with the interaction between human melanoma cells
and AHN-16, since AHN-16 bound the cell surface nor-
mally as assessed by flow cytometery (not shown).
In some cells, for example human neutrophils, the bind-
ing of a stimulus to its receptor on the cell surface results
in the activation of a signal transduction system that is
transient, and whose function is dependent on extracellu-
lar Ca2+ [35,36]. When calcium is absent during a critical
period following ligand-receptor coupling, the subse-
quent addition of calcium does not result in cell activa-
tion, and the cells may be partially desensitized to
subsequent stimulation in the presence of Ca2+ [35,36].
The role of extracellular Ca2+ was therefore further evalu-
ated. When calcium (10 mM) was added to the cells in
medium with EGTA immediately after adding them to the
plate, adhesion was normal. However, if the cells were
allowed to interact with the immobilized CD63 mAbs for
20 min before repleting the calcium, adhesion was not
restored by the calcium (not shown).
Identification of protein kinase activity associated with 
CD63
Since protein phosphorylation appears to be involved in
signaling by CD63 in A375SM cells, we questioned
whether protein kinase activity could be associated with
CD63 in A375SM cells as has been observed in neu-
trophils [15]. A375SM melanoma cells were solubilized in
a buffer containing Brij 58 as described in the Methods,
and the solubilized material was immunoprecipitated by
CD63 mAbs. When [γ-32P]ATP was added to the material
immunoprecipitated by the CD63 mAb AHN-16 (Fig 5,
lane 2) or the CD63 mAb AHN-16.1 (not shown), 32P was
reproducibly incorporated into three distinct proteins of
~208 to 236-kD, 53 to 58-kD, and 46 to 50-kD (labeled
EGTA inhibited cell adhesion to immobilized CD63 mAb Figure 4
EGTA inhibited cell adhesion to immobilized CD63 mAb. 
Top panel: plates were coated with 0.1 ug/ml of the indicated 
mAb and cell adhesion assays were carried out in the 
absence (hatched bars) or presence (solid bars) of 10 mM 
EGTA for 30 min as described in the Materials and Methods. 
CD63 mAbs: AHN-16, AHN-16.1, AHN-16.5; unclustered 
control mAb: U131, anti-MCSP mAb: 9.2.27. Bottom panel; 
plates were coated with 0.1 ug/ml of the CD63 mAb AHN-
16 as described in the Materials and Methods, and cell adhe-
sion assays were performed in either 10 mM EGTA, 10 mM 
EGTA plus 5 mM Ca2+, or 10 mM EGTA plus 10 mM Ca2+ for 
30 min as indicated. Results are shown as percent adhesion 
+/- SEM. A duplicate experiment gave similar results.Journal of Translational Medicine 2005, 3:42 http://www.translational-medicine.com/content/3/1/42
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1–3), that were not present when material was immuno-
precipitated by NMS (Fig 5, lane 1). In contrast, 32P was
reproducibly incorporated into a ~66-kD protein (labeled
4) in material immunoprecipitated by mAb 9.2.27 (Fig 5,
lane 3). Each of these four individual proteins were exam-
ined for phosphoamino acid content as described in the
Methods. The majority of radiolabel in each of these four
proteins was present on serine residues (Fig 6), demon-
strating the presence of serine kinase activity.
Discussion
Immunohistochemistry studies have characterized CD63
as the stage-specific melanoma-associated antigen ME491
[6-8]. Over expression of CD63 partially suppressed
malignant phenotypes of H-ras-transformed fibroblasts in
vivo[19], and transfection of melanoma cell lines also
suggested that CD63 can regulate melanoma cell function
[20,21]. The current study also demonstrates that CD63
can transduce signals in melanoma cells and alter
melanoma cell behavior. In addition, this study demon-
strates that CD63 is capable of transducing signals in
melanoma cells that requires extracellular Ca2+ and is
inhibited by the protein kinase C inhibitor chelerythrine.
Signaling by tetraspans, including the induction of cal-
cium-dependent cell-cell adhesion, has been reported in
other systems [37-39].
To examine potential signal transducing pathways
through which CD63 may act, an in vitro assay measuring
melanoma cell adhesion to immobilized mAbs was used.
We previously utilized this method for characterizing
molecular mechanisms of signal transduction from prote-
oglycan as well as integrin receptors in melanoma cells
[29,40]. Melanoma cells specifically adhered to immobi-
lized CD63 mAb, and the adhesion was inhibited by chel-
erythrine but not by genistein, suggesting that signaling
pathways involving protein kinase C activity, but not gen-
istein-sensitive tyrosine kinases, play a role in the stimula-
tion by CD63. The inhibitory activity of chelerythrine was
not due to cytotoxicity, since the chemicals did not affect
cell adhesion to immobilized mAb 9.2.27. The IC50 value
of chelerythrine is close to the value that inhibits the activ-
ity of protein kinase C in vitro[34], supporting the conclu-
sion that the inhibitory effect of chelerythrine on cell
adhesion to immobilized CD63 mAb is of a specific
nature.
CD63 may interact with different signaling molecules in
different cell types. In human neutrophils, tyrosine pro-
tein kinase activity has been reported to be associated with
CD63; most of this tyrosine kinase activity was found to
be due to the src family tyrosine kinases lyn and hck
which coimmunoprecipitated with CD63 in neutrophils,
suggesting that these kinases may play a role in signaling
via CD63 [15]. In the current study, we found serine pro-
Co-immunoprecipitation of protein kinase activity with  CD63 Figure 5
Co-immunoprecipitation of protein kinase activity with 
CD63. Panel A, Cells were solubilized in Brij solubilization 
buffer and immunoprecipitated with NMS (lane 1), the CD63 
mAb AHN-16 (lane 2), or the anti-MCSP mAb 9.2.27 (lane 
3), and the immunoprecipitates were incubated with [γ-
32P]ATP as described in the text. The resulting phosphopro-
teins were resolved by SDS-PAGE and visualized by autoradi-
ography as described in the text. Three phosphoproteins 
were reproducibly identified in CD63 mAb immunoprecipi-
tates (labeled 1–3 in lane 2). One phosphoprotein was repro-
ducibly identified in immunoprecipitates using the anti-MCSP 
mAb 9.2.27 (labeled 4 in lane 3). These four phosphoproteins 
were not seen in the immunoprecipitate using NMS (lane 1). 
Proteins used as molecular weight standards were: myosin 
heavy chain, 200,000; Escherichia coli β-galactosidase, 
116,000; bovine serum albumin, 66,000; ovalbumin, 45,000; 
and carbonic anhydrase, 29,000.Journal of Translational Medicine 2005, 3:42 http://www.translational-medicine.com/content/3/1/42
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tein kinase activity, but could not detect tyrosine kinase
activity, in immunoprecipitates using CD63 mAbs. Recent
studies have reported that CD63 in platelets modulates
spreading and tyrosine kinase activity [41]. Thus, these
results indicate that the interaction between CD63 and
these kinases is dependent upon the cell type. These data
also support a role for protein kinase C in CD63 signaling
in melanoma cells. CD63 has also been found to associate
with the β2 integrin CD18 in neutrophils and the β1
integrin in several other cells, including melanoma cells,
and this may also play a role in signaling by CD63 [15,42-
45]
Melanoma cell adhesion to immobilized CD63 mAb
required extracellular calcium, indicating that extracellu-
lar Ca2+ plays an important role in signaling by CD63 in
these cells. Addition of calcium to cells 20 min after inter-
action of cells with immobilized CD63 mAb resulted in
no adhesion. Thus, the interaction of melanoma cells
expressing CD63 to immobilized CD63 mAbs resulted in
the generation of a transient signal that required extracel-
lular calcium to effect melanoma cell adhesion. These
observations are similar to those reported with human
neutrophils where ligation of CD63 results in a transient
activation signal that requires extracellular calcium [15].
Conclusion
The current study demonstrates that CD63 is capable of
transducing signals in melanoma cells that requires extra-
cellular Ca2+ and is inhibited by the protein kinase C
inhibitor chelerythrine, and that CD63 is associated with
serine protein kinase activity in melanoma cells. This
associated protein kinase activity may play a role in the
mechanism whereby CD63 exerts its previously reported
effects on melanoma cell function [20,21].
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in figure 5.Journal of Translational Medicine 2005, 3:42 http://www.translational-medicine.com/content/3/1/42
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